External News
- Delaware Business Now
2 AstraZeneca lung cancer drugs perform well in late-stage trials
- OncLive
FDA Approval Insights: Adjuvant Pembrolizumab in Stage IB, II, or IIIA NSCLC
- AstraZeneca
Tagrisso demonstrated strong overall survival benefit in the ADAURA Phase III trial for adjuvant treatment of patients with early-stage EGFR-mutated lung cancer
- Yale News
YNHH’s Smilow Cancer Hospital pioneers new radiotherapy technology
- Business Wire
RefleXion Announces Installation of X1 Platform at Smilow Cancer Hospital at Yale New Haven
- Cure 20
Keytruda Approval Offers ‘Another Form of Insurance’ to Keep Lung Cancer From Returning
- OncLive
Dr. Park on Determining Treatment Approaches in NSCLC
- US News
Targeted Drug Tagrisso Could Be Advance Against Lung Cancer
- Cancer Network
Adjuvant Pembrolizumab Approval Adds to Prevention of Recurrent NSCLC
- OncLive
Dr. Herbst on the FDA Approval of Adjuvant Pembrolizumab in NSCLC
